Small cell carcinoma of the prostate: an immunohistochemical study - PubMed (original) (raw)
doi: 10.1097/00000478-200606000-00005.
Ralph Madeb, Patricia Bourne, Junyi Lei, Ximing Yang, Satish Tickoo, Zhengzhi Liu, Dongfeng Tan, Liang Cheng, Fadi Hatem, Jiaoti Huang, P Anthony di Sant'Agnese
Affiliations
- PMID: 16723847
- DOI: 10.1097/00000478-200606000-00005
Small cell carcinoma of the prostate: an immunohistochemical study
Jorge L Yao et al. Am J Surg Pathol. 2006 Jun.
Abstract
Small cell carcinoma of the prostate (SCPC) is morphologically similar to small cell carcinoma of the lung (SCLC) and maybe misinterpreted as Gleason pattern 5b prostate adenocarcinoma (HGPC). Recognition of SCPC is important because of its different clinical behavior. This study aims to characterize the immunophenotype of histologically classic SCPC using a comprehensive panel of markers, to better understand its histogenesis, aid in its classification, and evaluate potential therapeutic targets. Using the World Health Organization morphologic criteria for SCLC, 18 SCPC cases were identified; and studied for the following tumor marker groups: prostate specific/related, neuroendocrine, sex steroid hormone receptors, and prognostic/treatment target-related. Ten cases of UPC were used as controls. PSA was positive in 17% of SCPC and neuroendocrine markers were expressed in HGPC. PSA, TTF-1 and CD56 were the most helpful markers in differentiating between SCPC and HGPC (P<0.01), whereas bombesin/GRP, c-kit, bcl-2, and EGFR expression was more frequent in SCPC. SCPC is best diagnosed by following the World Health Organization diagnostic criteria for SCLC. Immunohistochemical markers can help separate SCPC from HGPC and may be useful in histologically borderline cases. Potential therapeutic targets are identified immunohistochemically in SCPC (Bombesin/GRP, c-kit, bcl-2, and EGFR).
Similar articles
- CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers.
Simon RA, di Sant'Agnese PA, Huang LS, Xu H, Yao JL, Yang Q, Liang S, Liu J, Yu R, Cheng L, Oh WK, Palapattu GS, Wei J, Huang J. Simon RA, et al. Hum Pathol. 2009 Feb;40(2):252-8. doi: 10.1016/j.humpath.2008.07.014. Epub 2008 Oct 5. Hum Pathol. 2009. PMID: 18835619 - Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases.
Wang W, Epstein JI. Wang W, et al. Am J Surg Pathol. 2008 Jan;32(1):65-71. doi: 10.1097/PAS.0b013e318058a96b. Am J Surg Pathol. 2008. PMID: 18162772 - Biallelic tumour suppressor loss and DNA repair defects in de novo small-cell prostate carcinoma.
Chedgy EC, Vandekerkhove G, Herberts C, Annala M, Donoghue AJ, Sigouros M, Ritch E, Struss W, Konomura S, Liew J, Parimi S, Vergidis J, Hurtado-Coll A, Sboner A, Fazli L, Beltran H, Chi KN, Wyatt AW. Chedgy EC, et al. J Pathol. 2018 Oct;246(2):244-253. doi: 10.1002/path.5137. Epub 2018 Aug 28. J Pathol. 2018. PMID: 30015382 - [Pulmonary neuroendocrine tumors in the new WHO 2015 classification: Start of breaking new grounds?].
Schnabel PA, Junker K. Schnabel PA, et al. Pathologe. 2015 May;36(3):283-92. doi: 10.1007/s00292-015-0030-2. Pathologe. 2015. PMID: 25956813 Review. German. - [Differential diagnosis of prostate cancer: impact of pattern analysis and immunohistochemistry].
Bonkhoff H. Bonkhoff H. Pathologe. 2005 Nov;26(6):405-21. doi: 10.1007/s00292-005-0794-x. Pathologe. 2005. PMID: 16205899 Review. German.
Cited by
- Unraveling molecular characteristics and tumor microenvironment dynamics of neuroendocrine prostate cancer.
Heimdörfer D, Artamonova N, Culig Z, Heidegger I. Heimdörfer D, et al. J Cancer Res Clin Oncol. 2024 Oct 16;150(10):462. doi: 10.1007/s00432-024-05983-0. J Cancer Res Clin Oncol. 2024. PMID: 39412660 Free PMC article. Review. - Regulation of Molecular Biomarkers Associated with the Progression of Prostate Cancer.
Martin-Caraballo M. Martin-Caraballo M. Int J Mol Sci. 2024 Apr 10;25(8):4171. doi: 10.3390/ijms25084171. Int J Mol Sci. 2024. PMID: 38673756 Free PMC article. Review. - Development and Characterisation of a New Patient-Derived Xenograft Model of AR-Negative Metastatic Castration-Resistant Prostate Cancer.
Turnham DJ, Mullen MS, Bullock NP, Gilroy KL, Richards AE, Patel R, Quintela M, Meniel VS, Seaton G, Kynaston H, Clarkson RWE, Phesse TJ, Nelson PS, Haffner MC, Staffurth JN, Pearson HB. Turnham DJ, et al. Cells. 2024 Apr 12;13(8):673. doi: 10.3390/cells13080673. Cells. 2024. PMID: 38667288 Free PMC article. - Case Report: 18F-PSMA PET/CT Scan in Castration Resistant Prostate Cancer With Aggressive Neuroendocrine Differentiation.
Bergamini M, Dalla Volta A, Caramella I, Bercich L, Fisogni S, Bertoli M, Valcamonico F, Grisanti S, Poliani PL, Bertagna F, Berruti A. Bergamini M, et al. Front Oncol. 2022 Jul 22;12:937713. doi: 10.3389/fonc.2022.937713. eCollection 2022. Front Oncol. 2022. PMID: 35936689 Free PMC article. - Neuroendocrine Neoplasms of the Female Genitourinary Tract: A Comprehensive Overview.
Virarkar M, Vulasala SS, Gopireddy D, Morani AC, Daoud T, Waters R, Bhosale P. Virarkar M, et al. Cancers (Basel). 2022 Jun 30;14(13):3218. doi: 10.3390/cancers14133218. Cancers (Basel). 2022. PMID: 35804996 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous